Minor
Suspected
설명
Rosuvastatin and colchicine share BCRP transporter-mediated elimination; colchicine may weakly increase rosuvastatin exposure, and both carry myotoxic potential that could be additive.
기전
Rosuvastatin is a substrate of BCRP (ABCG2) and OATP1B1/1B3; colchicine inhibits BCRP to a minor degree, potentially raising rosuvastatin AUC slightly; additive myopathy risk from two agents with muscle toxicity profiles.
임상적 중요성
The OATP/BCRP interaction is modest with colchicine; muscle toxicity cases have been reported for colchicine-statin combinations, although predominantly with CYP3A4-metabolised statins.
관리 방법
No routine dose adjustment is required; counsel patients to report muscle symptoms; measure CK if myopathy is suspected.